de Wit H, Svenson J, York A
Department of Psychiatry, The University of Chicago, MC3077, 5841 S. Maryland Avenue, Chicago, IL 60637, USA,
Psychopharmacology (Berl). 1999 Sep 1;146(1):33-41. doi: 10.1007/s002130051085.
Clinical studies have shown that the opioid antagonist naltrexone is effective in the treatment of alcoholism. However, the mechanism by which it produces this effect is not understood.
This study was designed to investigate the effect of acute naltrexone on consumption of ethanol in healthy, non-problem social drinkers.
Subjects (n=24) participated in an eight-session, within-subject, placebo-controlled choice procedure which measured ethanol preference and consumption. The procedure consisted of two blocks of four sessions in which subjects received either naltrexone (50 mg oral) or placebo 1 h before consuming an ethanol or placebo beverage. On the first two sessions of each block, subjects received a color-coded beverage containing ethanol (0.75 g/kg) or placebo, in five equal portions at 15-min intervals. On the next two sessions of each block, subjects chose which beverage they preferred (i.e., placebo or ethanol) and how much they wished to take, in unit doses (placebo or ethanol 0.15 g/kg/dose). The primary behavioral measures were (1) the number of times subjects chose ethanol over placebo, and (2) the number of doses they consumed. Subjects rated their mood states and subjective drug effects at regular intervals during each session.
Naltrexone did not alter the frequency of ethanol (versus placebo) choice. Although naltrexone did decrease the total number of ethanol doses subjects took (mean 2.7 doses after naltrexone; 3.4 doses after placebo), it also decreased the number of placebo "doses" subjects took on sessions when they chose the placebo beverage (mean 1.6 placebo doses after naltrexone; 2.8 doses after placebo). Ethanol produced its prototypic subjective effects (e.g., increased ratings of "feel drug", "like drug" and "high"), and these effects were not altered by naltrexone. Naltrexone produced mild sedative-like effects, and several subjects reported adverse effects such as nausea.
These findings show that naltrexone reduces ethanol consumption in healthy volunteers, as it does in alcoholics. However, this reduction was not specific to alcohol; subjects also consumed less of a non-alcoholic, placebo beverage. These findings suggest that naltrexone may reduce alcohol consumption by a non-specific mechanism.
临床研究表明,阿片类拮抗剂纳曲酮在治疗酒精中毒方面有效。然而,其产生这种效果的机制尚不清楚。
本研究旨在调查急性给予纳曲酮对健康、无酒精问题的社交饮酒者乙醇摄入量的影响。
受试者(n = 24)参与了一项为期八节的、受试者内、安慰剂对照的选择程序,该程序测量乙醇偏好和摄入量。该程序包括两个由四节组成的模块,在饮用乙醇或安慰剂饮料前1小时,受试者分别接受纳曲酮(口服50毫克)或安慰剂。在每个模块的前两节中,受试者以15分钟的间隔分五等份接受含有乙醇(0.75克/千克)或安慰剂的彩色编码饮料。在每个模块的接下来两节中,受试者选择他们更喜欢的饮料(即安慰剂或乙醇)以及他们希望服用的剂量(单位剂量,安慰剂或乙醇0.15克/千克/剂量)。主要行为指标为:(1)受试者选择乙醇而非安慰剂的次数;(2)他们摄入的剂量数。受试者在每节期间定期对他们的情绪状态和主观药物效果进行评分。
纳曲酮未改变乙醇(与安慰剂相比)的选择频率。虽然纳曲酮确实减少了受试者摄入的乙醇总剂量(纳曲酮后平均2.7剂;安慰剂后3.4剂),但它也减少了受试者在选择安慰剂饮料的节次中摄入的安慰剂“剂量”(纳曲酮后平均1.6剂安慰剂;安慰剂后2.8剂)。乙醇产生了其典型的主观效果(例如,“感觉像药物”、“喜欢药物”和“兴奋”评分增加),并且这些效果未被纳曲酮改变。纳曲酮产生了轻度的镇静样效果,并且有几名受试者报告了诸如恶心等不良反应。
这些发现表明,纳曲酮在健康志愿者中与在酗酒者中一样,能减少乙醇摄入量。然而,这种减少并非酒精特异性的;受试者对非酒精性安慰剂饮料的摄入量也减少了。这些发现表明,纳曲酮可能通过非特异性机制减少酒精摄入量。